However, it is also possible that DNMBP-rs10786578 genotypes are indeed a genetic biomarker for predicting the efficacy of post-resection 5-FU-based adjuvant chemotherapy in stage II/III CRC patients, and the lack of statistical significance could be attributed to the limitations of this study, particularly the small sample sizes. The gene discussed is DNMBP; the disease is colorectal carcinoma.